Trade Name: Zofran

Generic Name: ondansetron

Pt Weight: 86kg

Classification: antiemetics
Indications:
1. Prevention of nausea and vomiting associated with highly or moderately emetogenic
chemotherapy.
2. PO: Prevention of nausea and vomiting associated with radiation therapy.
3. Prevention and treatment of postoperative nausea and vomiting.
Why is your patient taking this drug? prevention of postoperative nausea (r/t scheduled
colonoscopy)
Standard doses and routes: IM: IV: (Adults) Prevention of postoperative nausea/vomiting 4 mg
before induction of anesthesia or postoperatively.
Patient Dose: 4mg I.V. PRN
Adverse Reactions & Side Fx:

Patient/Family Teaching:

CNS: headache, dizziness, drowsiness, fatigue, weakness

CV: TORSADE DE POINTES, QT interval prolongation
GI: constipation, diarrhea, abdominal pain, dry mouth, liver
enzymes
Neuro: extrapyramidal reactions
* CAPITALS indicate life-threatening.
Italics indicate most frequent.

1. Instruct patient to take

ondansetron as directed.
2. Advise patient to notify
health care professional
immediately if symptoms
of irregular heart beat or
involuntary movement of
eyes, face, or limbs occur.

Contraindications:
Hypersensitivity;
Orally disintegrating tablets contain aspartame and should not
be used in patients with phenylketonuria;
Congenital long QT syndrome;
Concurrent use of apomorphine.
Nursing Implications:
1. Drug may increase the risk of prolonged QT interval and
torsades de pointes (a potential fatal heart rhythm). Monitor
ECG in patients with congenital long QT syndrome, in those
with heart failure or bradyarrhythmias, and in those taking
other medications that can prolong the QT interval
2. Correct electrolyte abnormalities (hypokalemia or
hypomagnesemia) before infusing drug
3. Monitor liver function test results. Dont exceed 8mg in
patients with hepatic impairment
Lab Test Considerations: May increase ALT and AST levels